Wetzel Investment Advisors Inc. Sells 122 Shares of Johnson & Johnson $JNJ

Wetzel Investment Advisors Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,187 shares of the company’s stock after selling 122 shares during the quarter. Wetzel Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $640,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC grew its holdings in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new position in Johnson & Johnson during the first quarter valued at approximately $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson during the first quarter valued at approximately $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson during the first quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the first quarter valued at approximately $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on JNJ shares. Citigroup raised their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday, August 21st. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $181.40.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.3%

JNJ opened at $185.99 on Thursday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $186.56. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm’s fifty day moving average price is $175.45 and its two-hundred day moving average price is $162.51. The company has a market capitalization of $447.92 billion, a P/E ratio of 19.89, a P/E/G ratio of 2.36 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the previous year, the company earned $2.82 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.